Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 84Squamous Cell Carcinoma of Head and Neck 53Carcinoma, Non-Small-Cell Lung 30Head and Neck Neoplasms 29Colonic Neoplasms 23Neoplasm Metastasis 18Neoplasms 16Rectal Neoplasms 15Pancreatic Neoplasms 10Lung Neoplasms 10Mouth Neoplasms 8Carcinoma, Squamous Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Oropharyngeal Neoplasms 6Carcinoma 6Solid Tumors 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Gastrointestinal Neoplasms 5Breast Neoplasms 5Tongue Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Thyroid Neoplasms 3Recurrence 3Melanoma 3Digestive System Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Renal Cell 3Carcinoma, Pancreatic Ductal 3

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Recurrent Skin Squamous Cell Carcinoma × Cetuximab × 1 year × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡